Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 191 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 6, 7, 1, 33 and 6 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 9 and 2 molecules, respectively for Influenza A Virus, H1N1 Subtype Infections.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 5
Influenza A Virus, H1N1 Subtype Infections Overview 6
Therapeutics Development 7
Influenza A Virus, H1N1 Subtype Infections - Therapeutics under Development by Companies 9
Influenza A Virus, H1N1 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 12
Influenza A Virus, H1N1 Subtype Infections - Pipeline Products Glance 13
Influenza A Virus, H1N1 Subtype Infections - Products under Development by Companies 16
Influenza A Virus, H1N1 Subtype Infections - Products under Investigation by Universities/Institutes 20
Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 21
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 57
Drug Profiles 67
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 164
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 168
Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 169
Appendix 182

List of Tables

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2016 15
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2016 28
Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H2 2016 29
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc., H2 2016 30
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune, Inc., H2 2016 31
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Antigen Express, Inc., H2 2016 32
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 33
Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corporation, H2 2016 34
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H2 2016 35
Influenza A Virus, H1N1 Subtype Infections - Pipeline by ContraFect Corporation, H2 2016 36
Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax, Inc., H2 2016 37
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corporation, H2 2016 38
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gemmus Pharma Inc., H2 2016 39
Influenza A Virus, H1N1 Subtype Infections - Pipeline by iBio, Inc., H2 2016 40
Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016 41
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 42
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2016 43
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta, Inc., H2 2016 44
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 45
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2016 46
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc., H2 2016 47
Influenza A Virus, H1N1 Subtype Infections - Pipeline by MedImmune, LLC, H2 2016 48
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix, Inc., H2 2016 49
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mucosis B.V., H2 2016 50
Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides, Inc., H2 2016 51
Influenza A Virus, H1N1 Subtype Infections - Pipeline by NewLink Genetics Corporation, H2 2016 52
Influenza A Virus, H1N1 Subtype Infections - Pipeline by OPKO Health, Inc., H2 2016 53
Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc., H2 2016 54
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Pty Ltd, H2 2016 55
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 56
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 57
Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax, Inc., H2 2016 58
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Touchlight Genetics Limited, H2 2016 59
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, H2 2016 60
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart, Inc., H2 2016 61
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova AB, H2 2016 62
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Visterra, Inc., H2 2016 63
Influenza A Virus, H1N1 Subtype Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 64
Assessment by Monotherapy Products, H2 2016 65
Assessment by Combination Products, H2 2016 66
Number of Products by Stage and Target, H2 2016 68
Number of Products by Stage and Mechanism of Action, H2 2016 70
Number of Products by Stage and Route of Administration, H2 2016 72
Number of Products by Stage and Molecule Type, H2 2016 74
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2016 172
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects (Contd..1), H2 2016 173
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects (Contd..2), H2 2016 174
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects (Contd..3), H2 2016 175
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H2 2016 176